Early-Stage Diabetic Foot Ulcer Treatment
Embedded Files
537
537
million
million
diabetics worldwide*
diabetics worldwide*
* 2021 International Diabetes Federation
107
107
million
million
15%-25% of diabetics will develop a chronic, non-healing foot ulcer**
15%-25% of diabetics will develop a chronic, non-healing foot ulcer**
** 2022 - 2028 Market Growth Reports "Diabetic Foot Ulcers Treatment Market..."
26
26
million
million
24% of foot ulcers progress to require lower limb amputation***
24% of foot ulcers progress to require lower limb amputation***
*** July 2021 "Lower Limb Amputation Rates in Patients With Diabetes and an Infected Foot Ulcer: A Prospective Observational Study"
Non-Diabetic
Non-Diabetic
There is a balance between the Opioid Growth Factor (OGF) and the Opioid Growth Factor Receptor (OGFr), resulting in normal wound healing elements
Diabetic
Diabetic
Diabetics have a dysregulated OGF/OGFr, which suppresses key wound healing elements
Depressed cell migration and division
Decreased angiogenesis*
Reduced fibroblast** proliferation
Depressed collagen synthesis
Incomplete wound healing
Poor wound strength
Solution
Solution
Elkos' topical NTX blocks the OGFr, restoring healing at doses as low as 0.03%:
Reverses depressed cell replication
Restores Angiogenesis
Increases fibroblast proliferation
Reverses depressed collagen synthesis
Restores more complete wound healing
Results in normal tensile strength
IN THE NEWS
ElkosRX is moving towards clinical trials with their topical treatment
ElkosRx has developed an investigational treatment for diabetic foot ulcers (DFU) which, unlike the competition, targets the pathophysiology of DFUs
Page updated
Google Sites
Report abuse